Inclusion Criteria:

          -  Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular
             Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular
             Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.

          -  Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse/progression having
             attained a CR, PR, or stable disease post reinduction therapy.

          -  Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for
             patients > 16 years of age and Lansky for patients less than or equal to 16 years of
             age. See Appendix I for performance score.

          -  Life Expectancy Patients must have a life expectancy of > 6 weeks.

          -  Prior Therapy Patients must have fully recovered from the acute toxic effects of all
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry
                  onto this study (4 weeks if prior nitrosourea).

               2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
                  with a biologic agent.

          -  Organ Function Requirements

        Adequate Renal Function Defined As:

          -  Creatinine clearance or radioisotope GFR > 60 mL/min/1.73 m2 or

          -  A serum creatinine based on age/gender as follows:

        Age Maximum Serum Creatinine (mg/dL) Male Female

          -  12 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

          -  16 years 1.7 1.4

               -  Adequate Liver Function Defined As:

                    -  Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for
                       age, and

                    -  SGOT (AST) or SGPT (ALT) < 3 x upper limit of normal (ULN) for age for
                       presumed hepatic leukemia or lymphoma.

               -  Adequate Cardiac Function Defined As:

                    -  Shortening fraction of > 27% by echocardiogram, or

                    -  Ejection fraction of > 50% by radionuclide angiogram.

               -  Adequate Pulmonary Function Defined As:

                  • Normal respiratory rate for age and a pulse oximetry > 94% on room air unless
                  due to underlying malignancy.

               -  Peripheral Blood Stem Cell Collection

                  • Patients have a target of 5.0 x 106 CD34 (minimum of 2.5 x 106 CD34) PBSC
                  collected and cryopreserved prior to start of myeloablative conditioning

               -  All patients and/or their parents or legal guardians must sign a written informed
                  consent.

        Exclusion Criteria:

          -  Patient may not have had a prior stem cell transplant

          -  Patients must not have active CNS lymphoma

          -  Other concurrent investigational agents for treatment of B-cell lymphoma

          -  Pregnancy and/or active Breast Feeding

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation.

          -  Patient must not have an uncontrolled infection.

          -  Patient must not have ≥ Grade 3 neuropathy.